Liraglutide-associated acute pancreatitis

American Journal of Health-System Pharmacy

Volumn 69, Issue 5, 2012, Pages 386-389

  Knezevich, Emily ^a   Crnic, Theresa ^b   Kershaw, Scott ^c   Drincic, Andjela ^d  

^a CREIGHTON UNIVERSITY   (United States)

^b AURORA HEALTH CARE   (United States)

^c UNIVERSITY OF MONTANA   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Antidiabetic agents; Aspirin; Diabetes mellitus; Dosage; Glimepiride; Liraglutide; Metformin; Pancreatitis; Simvastatin; Tadalafil; Toxicity

Indexed keywords

ACETYLSALICYLIC ACID; AMYLASE; ENALAPRIL MALEATE; EXENDIN 4; GLIMEPIRIDE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN DETEMIR; INSULIN GLARGINE; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SIMVASTATIN; SITAGLIPTIN; TADALAFIL; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE;

ACUTE PANCREATITIS; ADULT; AMYLASE BLOOD LEVEL; ARTICLE; BEDTIME DOSAGE; BLOOD CELL COUNT; CASE REPORT; CHOLESTEROL BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; CREATININE CLEARANCE; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVENING DOSAGE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; MALE; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT REFUSAL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UPPER ABDOMINAL PAIN;

EID: 84857569892     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110221     Document Type: Article

References (18)

1. Peterson GE, Pollom RD. Liraglutide in clinical practice: dosing, safety, and efficacy. Int J Clin Pract. 2010; 64(suppl 167):35-43.
2. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007; 132:2131-57. (Pubitemid 46711096)
3. Montanya E, Sesti G. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagonlike peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clin Ther. 2009; 31:2472-88.
4. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2009; 32:1-11.
5. Rodbard HW, Jellinger PS, Davidson JA et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: an algorithm for glycemic control. Endocr Pract. 2009; 15:541-59.
6. Anderson SL, Trujillo JM. Association of pancreatitis with glucagon-like peptide-1 agonist use. Ann Pharmacother. 2010; 44:904-9.
7. Marre M, Shaw J, Brandle M et al. Liraglutide, a once daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009; 26:268-78.
8. Nauck M, Frid A, Hermansen K et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met). Diabetes Care. 2009; 32:84-90.
9. Garber A, Henry R, Ratner R et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomized, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009; 373:473-81.
10. Zinman B, Gerich J, Buse JB et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009; 32:1224-30.
11. Russell-Jones D, Vaag A, Schmitz O et al. LEAD-5 Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 Met+SU): a randomised controlled trial. Diabetologia. 2009; 52:2046-55.
12. Buse JB, Rosenstock J, Sesti G et al. LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009; 374:39-47.
13. Victoza (liraglutide) package insert. Princeton, NJ: Novo Nordisk A/S; 2010.
14. Lee PH, Stockton MD, Franks AS. Acute pancreatitis associated with liraglutide. Ann Pharmacother. 2011; 45:e22.
15. Noel RA, Braun DK, Patterson RE et al. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes. Diabetes Care. 2009; 32:834-8.
16. Naranjo C, Busto U, Sellers E et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30:239-45. (Pubitemid 12149145)
17. Balani AR, Grendell JH. Drug-induced pancreatitis incidence, management and prevention. Drug Saf. 2008; 31:823-37.
18. Engel SS, Williams-Herman DE, Golm GT et al. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract. 2010; 64:984-90.